| Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication R Di Micco, M Fumagalli, A Cicalese, S Piccinin, P Gasparini, C Luise, ... Nature 444 (7119), 638-642, 2006 | 2103 | 2006 |
| Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer S Bullman, CS Pedamallu, E Sicinska, TE Clancy, X Zhang, D Cai, ... Science 358 (6369), 1443-1448, 2017 | 1194 | 2017 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 696 | 2017 |
| Mitf regulation of Dia1 controls melanoma proliferation and invasiveness S Carreira, J Goodall, L Denat, M Rodriguez, P Nuciforo, KS Hoek, ... Genes & development 20 (24), 3426-3439, 2006 | 687 | 2006 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 623 | 2017 |
| Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib … R Salgado, C Denkert, C Campbell, P Savas, P Nuciforo, C Aura, ... JAMA oncology 1 (4), 448-455, 2015 | 602 | 2015 |
| NUMB controls p53 tumour suppressor activity IN Colaluca, D Tosoni, P Nuciforo, F Senic-Matuglia, V Galimberti, G Viale, ... Nature 451 (7174), 76-80, 2008 | 471 | 2008 |
| Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors R Dienstmann, J Rodon, A Prat, J Perez-Garcia, B Adamo, E Felip, ... Annals of oncology 25 (3), 552-563, 2014 | 402 | 2014 |
| Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle L De Mattos-Arruda, B Weigelt, J Cortes, HH Won, CKY Ng, P Nuciforo, ... Annals of oncology 25 (9), 1729-1735, 2014 | 400 | 2014 |
| Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma A Prat, A Navarro, L Paré, N Reguart, P Galván, T Pascual, A Martínez, ... Cancer research 77 (13), 3540-3550, 2017 | 396 | 2017 |
| Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response C Gorrini, M Squatrito, C Luise, N Syed, D Perna, L Wark, F Martinato, ... Nature 448 (7157), 1063-1067, 2007 | 383 | 2007 |
| RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, ... Annals of Oncology 29 (5), 1203-1210, 2018 | 346 | 2018 |
| HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer … A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, ... The lancet oncology 18 (4), 545-554, 2017 | 331 | 2017 |
| Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma PG Nuciforo, C Pellegrini, R Fasani, M Maggioni, G Coggi, A Parafioriti, ... Human Pathology 34 (7), 639-645, 2003 | 319 | 2003 |
| PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer IJ Majewski, P Nuciforo, L Mittempergher, AJ Bosma, H Eidtmann, ... Journal of Clinical Oncology 33 (12), 1334, 2015 | 255 | 2015 |
| Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration V Bossuyt, E Provenzano, WF Symmans, JC Boughey, C Coles, ... Annals of oncology 26 (7), 1280-1291, 2015 | 244 | 2015 |
| Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer JM Cejalvo, E Martínez de Dueñas, P Galván, S García-Recio, ... Cancer research 77 (9), 2213-2221, 2017 | 242 | 2017 |
| Frequent alterations in the expression of serine/threonine kinases in human cancers M Capra, PG Nuciforo, S Confalonieri, M Quarto, M Bianchi, M Nebuloni, ... Cancer research 66 (16), 8147-8154, 2006 | 226 | 2006 |
| Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor–negative melanoma … J Goodall, S Carreira, L Denat, D Kobi, I Davidson, P Nuciforo, RA Sturm, ... Cancer research 68 (19), 7788-7794, 2008 | 224 | 2008 |
| A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ... EMBO molecular medicine 10 (12), e9172, 2018 | 216 | 2018 |
